

# Atsushi Sakuraba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8387420/publications.pdf>

Version: 2024-02-01

150  
papers

4,848  
citations

109264

35  
h-index

110317

64  
g-index

153  
all docs

153  
docs citations

153  
times ranked

7296  
citing authors

#	ARTICLE	IF	CITATIONS
1	Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN- $\gamma$ axis. <i>Journal of Clinical Investigation</i> , 2008, 118, 2269-80.	3.9	559
2	Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. <i>International Journal of Medical Microbiology</i> , 2008, 298, 463-472.	1.5	281
3	Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 384-391.	0.5	269
4	Th1/Th17 Immune Response Is Induced by Mesenteric Lymph Node Dendritic Cells in Crohn's Disease. <i>Gastroenterology</i> , 2009, 137, 1736-1745.	0.6	211
5	Cytomegalovirus Is Frequently Reactivated and Disappears Without Antiviral Agents in Ulcerative Colitis Patients. <i>American Journal of Gastroenterology</i> , 2007, 102, 331-337.	0.2	183
6	Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2018, 19, 758-767.	5.1	128
7	T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. <i>Gut</i> , 2004, 53, 1303-1308.	6.1	125
8	An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment. <i>American Journal of Gastroenterology</i> , 2009, 104, 2990-2995.	0.2	117
9	Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. <i>Gut</i> , 2005, 54, 1254-1262.	6.1	113
10	Granulocytapheresis Is Useful as an Alternative Therapy in Patients with Steroid-refractory or -dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 251-257.	0.9	112
11	Animal models of inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2002, 37, 409-417.	2.3	96
12	Systematic review with meta-analysis: the efficacy and safety of CT-EP13, a biosimilar of anti-tumour necrosis factor- $\alpha$ agent (infliximab), in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1043-1057.	1.9	95
13	Covid-19 Reinfection: A Rapid Systematic Review of Case Reports and Case Series. <i>Journal of Investigative Medicine</i> , 2021, 69, 1253-1255.	0.7	95
14	Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. <i>American Journal of Gastroenterology</i> , 2017, 112, 1423-1429.	0.2	86
15	Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1259-1264.	0.9	82
16	Real-World Experience with Tofacitinib in IBD at a Tertiary Center. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1945-1951.	1.1	80
17	Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 113-120.	2.2	78
18	Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 484-494.	0.6	69

#	ARTICLE	IF	CITATIONS
19	Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn's Disease. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	67
20	Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor- $\alpha$ use in females with immune mediated diseases; a systematic review and meta-analysis. <i>Journal of Autoimmunity</i> , 2017, 76, 38-52.	3.0	65
21	Racial disparities in COVID-19 deaths reveal harsh truths about structural inequality in America. <i>Journal of Internal Medicine</i> , 2020, 288, 479-480.	2.7	64
22	Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion. <i>ACG Case Reports Journal</i> , 2018, 5, e56.	0.2	61
23	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 104-110.	2.4	60
24	C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. <i>Journal of Gastroenterology</i> , 2014, 49, 254-262.	2.3	56
25	Efficacy and Safety of Medical Therapy for Low Bone Mineral Density in Patients With Inflammatory Bowel Disease: A Meta-analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 32-44.e5.	2.4	54
26	Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease. <i>Gastroenterology</i> , 2004, 126, 829-839.	0.6	52
27	Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1480-1487.	0.9	50
28	The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 502-509.	0.9	50
29	Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3596-3601.	1.1	50
30	Response to "Correspondence on Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis" by Shi et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e29-e29.	0.5	50
31	Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor- $\alpha$ agents in rheumatic diseases; A systematic review and meta-analysis. <i>Journal of Autoimmunity</i> , 2017, 79, 4-16.	3.0	45
32	Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 373-385.	1.9	44
33	Population Difference in Allele Frequency of HLA-C*05 and Its Correlation with COVID-19 Mortality. <i>Viruses</i> , 2020, 12, 1333.	1.5	44
34	Response to: "Correspondence on Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis" by Yang et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e80-e80.	0.5	41
35	Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2022, 162, 88-108.e9.	0.6	41
36	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2017, 12, e0182900.	1.1	39

#	ARTICLE	IF	CITATIONS
37	Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: A prospective study. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 947-955.e2.	0.5	37
38	Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e1-e11.	1.1	37
39	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 637-643.	1.9	37
40	Prevalence of serum celiac antibody in patients with IBD in Japan. <i>Journal of Gastroenterology</i> , 2014, 49, 825-834.	2.3	36
41	Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 269-275.	0.5	36
42	A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. <i>Journal of Gastroenterology</i> , 2008, 43, 51-56.	2.3	34
43	Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 93-104.e5.	0.5	34
44	Natalizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 621-626.	0.9	33
45	EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 659-670.e18.	0.5	33
46	Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab monotherapy versus combination therapy in ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1177-1185.	1.4	30
47	Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 315-321.	0.6	27
48	Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. <i>Current Medical Research and Opinion</i> , 2016, 32, 1233-1241.	0.9	25
49	Is there a role for apheresis in gastrointestinal disorders?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2005, 2, 200-201.	1.7	24
50	Mucosal Healing Is Associated with Improved Long-term Outcome of Maintenance Therapy with Natalizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2577-2583.	0.9	24
51	Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1105-1110.	0.6	24
52	Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 318-331.	2.3	22
53	Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1919-1925.	2.4	21
54	Risk of Colorectal Cancer in Chronic Kidney Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 796-804.	1.1	21

#	ARTICLE	IF	CITATIONS
55	Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. <i>Digestive Diseases and Sciences</i> , 2021, 66, 577-586.	1.1	21
56	Response to "Correspondence on "Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis" by Gremese et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-219337.	0.5	21
57	Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. <i>Journal of Hematology and Oncology</i> , 2022, 15, 15.	6.9	21
58	The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study. <i>International Journal of Colorectal Disease</i> , 2012, 27, 947-952.	1.0	20
59	Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1027-1031.	0.9	20
60	Risk of Fractures in Inflammatory Bowel Diseases. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 441-448.	1.1	20
61	Response to: "Correspondence on "Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis" by Lee. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e84-e84.	0.5	20
62	Update on the Management of Ulcerative Colitis. <i>Current Gastroenterology Reports</i> , 2011, 13, 475-485.	1.1	18
63	Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 236-241.	0.9	18
64	Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100104.	2.0	16
65	Risk of Colorectal Cancer in Serrated Polyposis Syndrome: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 622-630.e7.	2.4	16
66	The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 162-168.	1.9	15
67	Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1143-1151.	1.4	15
68	The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. <i>Gut</i> , 2021, 70, 2076-2084.	6.1	15
69	Granulocyte and Monocyte Adsorption Apheresis Therapy Modulates Monocyte-Derived Dendritic Cell Function in Patients With Ulcerative Colitis. <i>Therapeutic Apheresis and Dialysis</i> , 2009, 13, 138-146.	0.4	14
70	Approach to Optimize Anti-TNF Therapy in Patients With IBD. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 83-90.	0.3	14
71	Preoperative Right-Sided Cardiac Congestion Is Associated with Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1518-1524.	1.1	14
72	Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. <i>World Journal of Gastroenterology</i> , 2021, 27, 2312-2324.	1.4	13

#	ARTICLE	IF	CITATIONS
73	Ulcerative colitis: prevention of relapse. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 341-351.	1.4	12
74	Combination Therapy with Infliximab and Thiopurine Compared to Infliximab Monotherapy in Maintaining Remission of Postoperative Crohn's Disease. <i>Digestion</i> , 2015, 91, 233-238.	1.2	12
75	A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 933-940.	1.9	12
76	Per oral endoscopic myotomy as salvage therapy in patients with achalasia refractory to endoscopic or surgical therapy is technically feasible and safe: Systematic review and meta-analysis. <i>Digestive Endoscopy</i> , 2020, 32, 1042-1049.	1.3	12
77	Worldwide association of lifestyle-related factors and COVID-19 mortality. <i>Annals of Medicine</i> , 2021, 53, 1531-1536.	1.5	12
78	Intermittent Granulocyte and Monocyte Apheresis Versus Mercaptopurine for Maintaining Remission of Ulcerative Colitis: A Pilot Study. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 213-218.	0.4	11
79	Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 596-606.	1.1	11
80	Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 43-51.	1.1	11
81	Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1016-1024.	1.1	10
82	Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. <i>Epigenetics</i> , 2021, 16, 1317-1334.	1.3	10
83	Efficacy of various endoscopic modalities in detecting dysplasia in ulcerative colitis: A systematic review and network meta-analysis. <i>World Journal of Gastrointestinal Endoscopy</i> , 2020, 12, 159-171.	0.4	10
84	Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis. <i>World Journal of Hepatology</i> , 2020, 12, 239-252.	0.8	10
85	Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. <i>Intestinal Research</i> , 2022, 20, 240-250.	1.0	10
86	Management of inflammatory bowel disease: past, present and future. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 303-305.	1.3	9
87	The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 676-690.	0.6	9
88	Coronavirus Disease 2019 (COVID-19) Meets Obesity: Strong Association between the Global Overweight Population and COVID-19 Mortality. <i>Journal of Nutrition</i> , 2021, 151, 9-10.	1.3	9
89	Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1386-1394.	0.9	9
90	Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1365-1372.	1.9	8

#	ARTICLE	IF	CITATIONS
91	Risk of Cancers in Patients with Pediatric Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. <i>Journal of Pediatrics</i> , 2021, 229, 102-117.e36.	0.9	8
92	The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. <i>Digestion</i> , 2021, 102, 767-775.	1.2	8
93	Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2020, 27, 1620-1625.	0.9	7
94	Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease. <i>Intestinal Research</i> , 2022, 20, 303-312.	1.0	7
95	Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn's disease patients. <i>Annals of Medicine</i> , 2022, 54, 886-892.	1.5	7
96	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2090-2095.	1.4	6
97	Low Skeletal Muscle Index Adjusted for Body Mass Index Is an Independent Risk Factor for Inflammatory Bowel Disease Surgical Complications. <i>Crohn's &amp; Colitis 360</i> , 2020, 2, .	0.5	6
98	Football and COVID-19 risk: correlation is not causation. <i>Clinical Microbiology and Infection</i> , 2021, 27, 291-292.	2.8	6
99	Two Complex Cases of Hermansky-Pudlak Syndrome Highlight a Potential Biologic Explanation for an Associated Crohn's Disease Phenotype. <i>ACG Case Reports Journal</i> , 2017, 4, e14.	0.2	5
100	Intensive therapy of granulocyte and monocyte adsorption apheresis induces rapid remission in patients with ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, A522.	0.6	4
101	Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 987-988.e1.	2.4	4
102	Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. <i>International Journal of Colorectal Disease</i> , 2020, 35, 2113-2116.	1.0	4
103	Correlation Between Clinical, Endoscopic, and Histologic Disease Activity in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2012, 107, S694.	0.2	4
104	Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab. <i>American Journal of Gastroenterology</i> , 2015, 110, S783-S784.	0.2	4
105	Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1291-1297.	0.9	3
106	Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2785-2793.	1.4	3
107	P454 Can calcineurin inhibitors induce a durable remission that is maintained with vedolizumab in IBD?. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S309-S309.	0.6	2
108	696 fFUT2 Genotype Is Not Associated With Disease Phenotype or Outcomes in Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, S407-S409.	0.2	2

#	ARTICLE	IF	CITATIONS
109	A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. <i>Crohn's &amp; Colitis</i> 360, 2022, 4, .	0.5	2
110	Parastomal Variceal Bleeding Attributed to Obstructive Pathology Successfully Treated by Percutaneous Variceal Embolization. <i>ACG Case Reports Journal</i> , 2014, 1, 217-219.	0.2	1
111	Editorial: CTâ€P13, a biosimilar of antiâ€tumor necrosis factorâ€alpha agent (infliximab), in inflammatory bowel diseases â€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1372-1372.	1.9	1
112	Longitudinal Evaluation with Capsule Endoscopy for Disease Monitoring of Patients with Crohn's Disease is Feasible, Valid, and Safe. <i>Gastroenterology</i> , 2017, 152, S770-S771.	0.6	1
113	Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively with Anti-integrin and Anti-Tumor Necrosis Factor Agents. <i>Gastroenterology</i> , 2017, 152, S574.	0.6	1
114	Efficacy of Various Endoscopic Modalities in Detecting Neoplasia in Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. <i>Gastroenterology</i> , 2017, 152, S731-S732.	0.6	1
115	Gastrointestinal cancers in patients with cystic fibrosis â€“ Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e369.	5.1	1
116	Safety of nontumor necrosis factorâ€targeted biologics in the COVIDâ€19 pandemic. <i>Journal of Medical Virology</i> , 2021, 93, 714-716.	2.5	1
117	INTERMITTENT THERAPY WITH GRANULOCYTE AND MONOCYTE APHAERESIS MAINTAINS REMISSION IN ULCERATIVE COLITIS. <i>American Journal of Gastroenterology</i> , 2004, 99, S258-S259.	0.2	1
118	Dysregulated Immune Response in Mesenteric Lymph Nodes of Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, S321.	0.2	1
119	Age of Diagnosis Is Associated with Disease Phenotype and Behavior in Crohn's Disease Patients. <i>American Journal of Gastroenterology</i> , 2013, 108, S537-S538.	0.2	1
120	Crohn's Disease, Antibiotic Use, and Recent Health Care Exposures Are Associated with <i>Clostridium difficile</i> Isolation in IBD. <i>American Journal of Gastroenterology</i> , 2016, 111, S270-S271.	0.2	1
121	Low dose of 6-mercaptopurine (30mg/day) or azathioprine (50mg/day) is effective for the maintenance of remission in IBD. <i>Gastroenterology</i> , 2003, 124, A200-A201.	0.6	0
122	Phenotypic and functional analysis of dendritic cells isolated from the mesenteric lymph nodes of human inflammatory bowel disease. <i>Gastroenterology</i> , 2003, 124, A322.	0.6	0
123	Platelet activation and interaction with leukocytes in patients with ulcerative colitis: a novel marker for prediction of efficacy of granulocyte and monocyte adsorption apheresis. <i>Gastroenterology</i> , 2003, 124, A197.	0.6	0
124	The Risk of Formation of Neutralizing Antibodies. <i>Frontiers of Gastrointestinal Research</i> , 0, , 95-99.	0.1	0
125	Novel Topics in Inflammatory Bowel Disease. <i>BioMed Research International</i> , 2016, 2016, 1-1.	0.9	0
126	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 776-777.	2.4	0



#	ARTICLE	IF	CITATIONS
127	Tu1917 Risk of Pregnancy Related Complications With Anti-TNFalpha Therapy in Immune Mediated Diseases; A Systematic Review and Meta-Analysis. Gastroenterology, 2016, 150, S977.	0.6	0
128	Tu1906 Risk of Cancer Recurrence Among Individuals Exposed to Anti-Tumor Necrosis Factor Therapy: A Meta-Analysis of Observational Studies. Gastroenterology, 2016, 150, S973-S974.	0.6	0
129	Mo1293 Characterization of Disease Related Factors in Microscopic Colitis. Gastroenterology, 2016, 150, S690.	0.6	0
130	The "Moonsault" maneuver: retroflexed ileocecal valve insertion. Gastrointestinal Endoscopy, 2016, 83, 663.	0.5	0
131	The Benefit of Combination Therapy Depends on Disease Phenotype and Duration in Crohn's Disease: A Prospective Cohort Study. Gastroenterology, 2017, 152, S58.	0.6	0
132	Efficacy of Calcineurin Inhibitors During Induction and Maintenance of Remission with Vedolizumab in IBD. Gastroenterology, 2017, 152, S405.	0.6	0
133	Pharmacologic Therapies for Severe Steroid Refractory Hospitalized Ulcerative Colitis: A Network Meta-Analysis. Gastroenterology, 2017, 152, S592.	0.6	0
134	Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 905-906.	1.9	0
135	Gastrointestinal cancer risk in cystic fibrosis: more exploration is needed " Authors' reply. Lancet Oncology, The, 2018, 19, e333.	5.1	0
136	Sa1277 POEM AS SALVAGE THERAPY FOR ACHALASIA AFTER FAILED ENDOSCOPIC OR SURGICAL THERAPY IS TECHNICALLY FEASIBLE AND SAFE - A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastrointestinal Endoscopy, 2019, 89, AB201.	0.5	0
137	765 Low Skeletal Muscle Index Is an Independent Risk Factor for Inflammatory Bowel Disease Surgical Complications. American Journal of Gastroenterology, 2019, 114, S446-S446.	0.2	0
138	24 ENDOSCOPIC AND CLINICAL CHARACTERISTICS OF POUCHITIS INVOLVING THE RECTAL CUFF IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY PROCTOCOLECTOMY WITH ILEAL POUCH-ANAL ANASTOMOSIS. Inflammatory Bowel Diseases, 2020, 26, S13-S14.	0.9	0
139	COVID-19 mortality and gross domestic product loss: A wake-up call for government leaders. World Journal of Clinical Infectious Diseases, 2021, 11, 35-37.	0.5	0
140	An Age-Old Problem: The Surgical Treatment of Complete Rectal Prolapse. Gastroenterology Insights, 2021, 12, 347-349.	0.7	0
141	A Multicenter, Randomized, Controlled Trial between Weekly and Semiweekly Treatment with Granulocyte and Monocyte Adsorption Apheresis for Active Ulcerative Colitis. American Journal of Gastroenterology, 2005, 100, S321.	0.2	0
142	Capsule Endoscopy Is Useful in Assessing Intestinal Lesions of Behcet's Disease. American Journal of Gastroenterology, 2006, 101, S532.	0.2	0
143	Biologic Therapy of Crohn's Disease: Infliximab. , 2012, , 413-432.		0
144	Meta-Analysis of the Efficacy and Safety of Bisphosphonate Therapy in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2012, 107, S672.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Natalizumab in Crohn's Disease: Results from a U.S. Tertiary IBD Center. American Journal of Gastroenterology, 2012, 107, S672-S673.	0.2	0
146	Efficacy and Safety of Tacrolimus Therapy for Severe and Steroid-refractory Ulcerative Colitis: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2015, 110, S828-S829.	0.2	0
147	Comparison of Real World Outcomes of Adalimumab and Infliximab for Patients With Moderate or Severe Ulcerative Colitis in the United States. American Journal of Gastroenterology, 2015, 110, S772.	0.2	0
148	Feasibility and Diagnostic Yield of Trans-Nasal Esophagogastroduodenoscopy (TN-EGD) Compared to Conventional EGD (C-EGD) for Screening of Upper Gastrointestinal Disease: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2015, 110, S968.	0.2	0
149	Predictive Probability Score for 30-Day Readmissions in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2016, 111, S272-S273.	0.2	0
150	Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis. World Journal of Hepatology, 2020, 12, 229-242.	0.8	0